Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Morphic Holding, Inc. (MORF)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
37.42-0.15 (-0.40%)
At close: 04:00PM EDT
38.17 +0.75 (+2.00%)
After hours: 05:37PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Performance Outlook
Previous Close37.57
Open37.15
Bid37.32 x 800
Ask59.29 x 900
Day's Range37.08 - 37.78
52 Week Range19.23 - 49.24
Volume422,545
Avg. Volume367,821
Market Cap1.479B
Beta (5Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MORF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Morphic Holding, Inc.
    Daily – Vickers Top Buyers & Sellers for 10/28/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    5 months agoArgus Research
View more
  • GlobeNewswire

    Morphic to Present at TD Cowen 43rd Annual Health Care Conference

    WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate a panel discussion focused on new approached to treat gastroenterological diseases and a corporate fireside chat at the TD Cowen 43rd Annual Health Care Conference. Presentation Information GI/Microbiome Panel Discussion9:10 AM E

  • GlobeNewswire

    Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022

    -Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23- -Launched EMERALD-2 phase 2b global randomized trial of MORF-057 in ulcerative colitis- -Ended 2022 with $348 million in cash and equivalents; ~$100 million from February private placement extends cash runway into second half of 2026 WALTHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generat

  • GlobeNewswire

    Morphic to Present at SVB Leerink Global Healthcare Conference

    WALTHAM, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the virtual SVB Leerink Global Healthcare conference including a hosted fireside chat. Presentation Information 8:40 AM ET, Thursday February 16, 2023 Fireside Chat at the SVB Leerink Conference A live webcast of the presentati

Advertisement
Advertisement